


## Meprednisone

Cat. No.:	HY-B0243
CAS No.:	1247-42-3
Molecular Formula:	C <sub>22</sub> H <sub>28</sub> O <sub>5</sub>
Molecular Weight:	372.45
Target:	Glucocorticoid Receptor; Autophagy
Pathway:	Immunology/Inflammation; Vitamin D Related/Nuclear Receptor; Autophagy
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 100 mg/mL (268.49 mM)

\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.6849 mL	13.4246 mL	26.8492 mL
	5 mM	0.5370 mL	2.6849 mL	5.3698 mL
	10 mM	0.2685 mL	1.3425 mL	2.6849 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 3 mg/mL (8.05 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 3 mg/mL (8.05 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 3 mg/mL (8.05 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Meprednisone is a glucocorticoid and a methylated derivative of prednisone. Target: Glucocorticoid Receptor. Meprednisone is a glucocorticoid and a methylated derivative of prednisone. The methylprednisone to MPL area under the curve ratio decreased from 0.19 +/- 0.04 in control to 0.14 +/- 0.03 in ketoconazole-treated rats (P less than .05) due to altered interconversion between these steroids. An improved pharmacokinetic/dynamic receptor/gene-mediated model characterized the steroid receptor binding and induction of tyrosine aminotransferase activity after i.v. MPL sodium succinate (10 mg/kg). In contrast to previous in vitro studies, ketoconazole at maximally tolerated doses failed to antagonize the steroid receptor-mediated activity of MPL [1].

---

## REFERENCES

[1]. Scheuer, E. and E. Warshaw, Allergy to corticosteroids: update and review of epidemiology, clinical characteristics, and structural cross-reactivity. Am J Contact Dermat, 2003. 14(4): p. 179-87.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA